key: cord-0961287-g6sthuvr
authors: Blanco, Omar R.; Dorta, Dayamí; Hernández, Carlos A.; Abreu, Daymí; Domínguez, Andy G.; Luna, Yaramis; Valdivia, Onel; Pérez-Bernal, Maylín; Tamayo, Celia; Lemos, Gilda; Pasarón, Ivis; Pérez, Joel J.; Benítez, Liudmila; Bequet-Romero, Mónica; Quintero, Anitza Fraga; Cabrera, Yeosvany; Pérez, Enrique R.
title: Murine monoclonal antibodies against RBD of the SARS-CoV-2 spike protein as useful analytical tools for subunit vaccine development and clinical trials
date: 2021-11-26
journal: J Immunol Methods
DOI: 10.1016/j.jim.2021.113195
sha: aee6bf7378782d0c2f7d3781a410d884e5212f22
doc_id: 961287
cord_uid: g6sthuvr

COVID-19 pandemic poses a serious threat to human health; it has completely disrupted global stability, making vaccine development an important goal to achieve. Monoclonal antibodies play an important role in subunit vaccines strategies. In this work, nine murine MAbs against the RBD of the SARS-CoV-2 spike protein were obtained by hybridoma technology. Characterization of purified antibodies demonstrated that five of them have affinities in the order of 10(8) L/mol. Six of the eight MAbs showed specific recognition of different recombinant RBD-S antigens in solution. Studies of the additivity index of anti-RBD antibodies, by using a novel procedure to determine the additivity cut point, showed recognition of at least five different epitopes. The MAbs CBSSRBD-S.11 and CBSSRBD-S.8 revealed significant neutralizing capacity against SARS-CoV-2 in an ACE2-RBD binding inhibition assay (IC(50) = 85.5pM and IC(50) = 122.7pM, respectively) and in a virus neutralizing test with intact SARS-CoV-2 (VN(50) = 0.552 nM and VN(50) = 4.854 nM, respectively) when D614G strain was used to infect Vero cells. Also CBSSRBD-S.11 neutralized the SARS-CoV-2 strains Alpha and Beta: VN(50) = 0.707 nM and VN(50) = 0.132 nM, respectively. The high affinity CBSSRBD-S.8 and CBSSRBD-S.7 recognized different epitopes, so they are suitable for the development of a sandwich ELISA to quantitate RBD-S recombinant antigens in biomanufacturing processes, as well as in pharmacokinetic studies in clinical and preclinical trials.

The coronavirus induced disease was unknown until outbreak in December 2019 when the first patients were detected in Wuhan, China, and the studies identified a new coronavirus as etiological agent: the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Gorbalenya et al., 2020; Zhou et al., 2020) . A few months after its epidemic outbreak COVID-19 became a pandemic that represents a serious threat to human health and has changed entire worldwide dynamics affecting not only public health but education, economy and so many other spheres (UN News, 2020; WHO, 2020a) . Globally, there have been 3,937,437 deaths from COVID-19, reported to the WHO as of June 30, 2021 (WHO, 2021b . In addition, novel variants of SARS-CoV-2 have emerged during human to human transmission and its long-term consequences are still under study (GOV.UK, 2021a Valdés et al., 2021; Valdes-Balbin et al., 2021; Zhang et al., 2021) .

Coronaviridae is a broad family of viruses including SARS-CoV-2 that it is very similar to SARS-CoV but ostensibly more contagious due to a higher affinity to the receptor angiotensinconverting enzyme 2 (ACE-2) which is expressed on numerous cells, including lung, heart, kidney, and intestine cells. Its host-cell infection mechanism involves the subunit 1 (S1) located in the N-terminal of the spike protein (S) that recognizes and binds ACE-2 through the receptorbinding domain (RBD) Gorbalenya et al., 2020; Kuba et al., 2005; Li et al., 2003; Yan et al., 2021 Yan et al., , 2020 .

The availability of safe and effective vaccines has shown to represent a radical change in the face of the COVID-19 pandemic (WHO, 2021c) . Subunit vaccines stand out among the different development strategies due to their advantages of safety, stability and more feasible storage conditions compared to others, 30 % of vaccines in clinical development are been deployed in subunit platform (WHO, 2021d) . Several vaccines strategies against SARS-CoV-2 target the S protein because it induces a high immune response in humans and specifically the receptorbinding domain of S protein (RBD-S) induces the highest titers of neutralizing antibodies (He et al., 2004; Kyriakidis et al., 2021; Limonta-Fernández et al., 2021; Qi et al., 2020; Valdés et al., 2021; Valdes-Balbin et al., 2021; Zhu et al., 2013) .

MAbs are displaying a crucial role in the investigations related to COVID-19, which are focused in effective therapies, vaccines design and SARS-CoV-2 detailed characterization (Taylor et al., be produced in VeroE6 cells (Makdasi et al., 2021) . Other investigations report the obtainment of mouse MAbs by hybridoma technology (Chapman et al., 2021; Guo et al., 2021) and its subsequent evaluation for application in molecular pathology as humanized MAbs .

Several anti SARS-CoV-2 MAbs entered clinical trials during the second half of 2020 (Marovich et al., 2020) . Until date, six neutralizing MAbs obtained an Emergency Use Authorization by the regulatory agencies of United States and South Korea, and others are being evaluated in clinical trials. MAbs authorized or in development are directed to the RBD, all of them are fully human and the majority was obtained from SARS-CoV-2-immune donors (Corti et al., 2021) .

Furthermore, murine MAbs are being applied as biological reagents offering analytical support determination of SARS-CoV-2 spike antigens by design of various immunodetection systems required in biomanufacturing, diagnostic and virus neutralization tests Perera et al., 2020; Tan et al., 2020) .

This work describes the obtainment of mouse MAbs with specific recognition of the recombinant RBD-S protein of SARS-CoV-2 suitable for analytical methods required in the researchdevelopment and production of subunit vaccines as well as in clinical trials. MAbs were characterized with respect to important features they should have in order to be used as reagents such as: affinity, specificity against different recombinant RBD antigens, epitope specificity among each MAb pairs and potential neutralizing activity. The neutralizing murine MAbs could be humanized in order to test their therapeutic potential.

Different recombinant antigens (table 1) corresponding to fragments of the RBD-S of SARS CoV-2. RBD r1 , RBD r4 were supplied by the Center for Molecular Immunology, RBD r2 (Limonta-Fernández et al., 2021) and RBD r3 by the Center for Genetic Engineering and Biotechnology and RBD r5 (Valdes-Balbin et al., 2021) 

Spleen cells from higher titer immunized mouse were fused with exponentially growing mouse myeloma cells line P3X63Ag8.653 three days after booster injection. A mixture of 100×10 6 spleen cells and 10×10 6 myeloma cells was fused using 50% (w/v) polyethylene glycol solution (Sigma, Hybri-Max) according to a published modification of the Köhler and Milstein protocol (Galfrè and Milstein, 1981; Köhler and Milstein, 1975) . The cells were cultured in RPMI 1640 Hybri-Max, USA) and were distributed in 96-well culture plates. The plates were incubated at 37°C in a 5% CO 2 atmosphere. The culture supernatants of the hybrid cell colonies were tested for anti-RBD-S antibodies secretion by the specific ELISA described above. Hybridomas from ELISA positive wells were collected and repetitively cloned by limiting dilution method at a rate of one cell/well.

Identification of MAbs class and subclass was carried out using a mouse monoclonal antibody isotyping kit (Sigma, Germany) according to the manufacturer's recommendations. Plates were coated with 100µL/well of 10µg/mL of RBD r1 diluted in 0.01 M carbonate-bicarbonate buffer solution, pH 9.6 and incubated 2h at 37°C

The selected hybridoma cell lines were washed in RPMI-1640 medium (Gibco, USA), centrifuged at 180 × g for 10 min at RT and resuspended in RPMI-1640 medium, until a concentration of 2×10 6 cells/mL. The cell suspension was injected intraperitoneally to BALB/c mice, 1mL per mouse. Ten days before the injection, the mice peritoneum was stimulated with paraffinic mineral oil. Seven days after, the ascites fluid was extracted by puncture of the peritoneum and clarified by centrifugation at 1125 × g for 30 min at RT.

The ascites fluid was filtered through 0.45μm glass wool, precipitated with 50% (w/v) of ammonium sulfate and centrifuged 30 min at 6000 × g. The pellet was resuspended in 1.5M glycine, 3M NaCl, pH 8.9, and loaded onto an nProtein A Sepharose Fast Flow matrix (Cytiva, USA). Elution was carried out with 0.1M citrate buffer, pH 6.0. The chromatographic profile was checked by measuring the absorbance at 280 nm. The eluate was neutralized with 2 M Tris-HCl and dialyzed in 20mM Tris-HCl, 150mM NaCl, pH 7.0, during 16 h, and then filtered through 0.2µm membrane. A final concentration of 0.02% (v/v) of thimerosal was added as preservative.

Purified samples were evaluated by densitometric analysis of SDS-PAGE 12.5%.

To measure the affinity constant of eight MAbs generated against the recombinant SARS-CoV-2

Spike Protein receptor binding domain (RBD r1 ) the methodology of Beatty JD et al., 1987 was followed, by the indirect antibody capture ELISA used for hybridoma screening described above, with modifications. Eight plates were divided into four sections of two rows each one and coated from bottom to top with concentrations of 1.25, 2.5, 5 and 10µg/mL of RBD r1 . Each antibody was tested on a separate plate by performing 1:4 serial dilutions from the third column to the 12 th , the concentrations were between 10µg/mL and 38pg/mL. First and second columns of all plates were reserved as blanks of the assay. The affinity constant (K aff ) was calculated by the formula:

where n represents the ratio between the highest and the lowest antigen concentration for each of the six possible comparisons between the four antigen concentrations used. In a comparison between two antigen concentrations, [Ab] 1 represents the molar antibody concentration calculated The K aff value in L/mol for each antibody represents the mean ± the standard deviation (SD) of the six calculated K aff values.

In this procedure, the indirect ELISA described above was applied, with the difference that it includes a step of inhibition in solution of the MAbs with the recombinant antigens RBD r1 and RBD r2 for 1 hour at RT. The antigen was added in each inhibition mixture in molar concentrations greater than 100 times the concentration of the MAbs. Inhibition was calculated as follows:

The A492nm values were the mean of triplicate measurements.

The additivity test described by Friguet and colleagues (with adjustments in the cut point calculation procedure) was applied in order to evaluate whether two MAbs recognize different antigenic sites (Friguet et al., 1983) . This test was performed using the previously described indirect ELISA with small modifications. The plates were coated with 100µL/well of 0.7µg/mL of RBD r1 . Each pair of MAbs was added at saturating concentration for this coating (10µg/mL).

The additivity index (AI) of a pair of antibodies was defined as follows:

where A 1 , A 2 and A 1+2 are the A492nm reached in the ELISA with the first MAb alone, the second MAb alone, and the two MAbs together, respectively. If the two antibodies randomly bind to the same site then A 1+2 must be equal to the mean value of A 1 and A 2 and the additivity index should theoretically equal to 0%. Conversely, if the two antibodies bind independently to J o u r n a l P r e -p r o o f different sites, A 1+2 must be the sum of A 1 and A 2 and AI should be theoretically equal to 100%.

To establish an objective cut point of AI values that indicate that two antibodies recognize different antigenic sites, the AI of the same antibody (AI zero ) was calculated. To this aim, it was established that A 1 and A 2 represent the experimental absorbance values of the same antibody at two different wells on the ELISA plate and A 1+2 represents the experimental absorbance value of the same antibody at double saturating concentration. The cut point (CP) was defined as:

where the AI zero mean and the SD of the seven MAbs tested are used, t 0.05,df is the one-tail critical value determined from t-distribution corresponding to a 5% false-additivity rate and "df" are the degrees of freedom that depend on the numbers of MAbs analyzed.

Costar® 3590 high binding polystyrene 96-well microtiter plates were coated with 100 µL/well of MAb CBSSRBD-S.8, at 5µg/mL in 0.1M carbonate-bicarbonate buffer, pH 9.6, for two hours at 37°C. The plates were then washed tree times with PBST. These washing conditions were applied in all steps of the ELISA, except after blocking. Then 380 µL/well of blocking solution (3% (w/v) nonfat dried milk powder in PBS) was added to the plates and incubated for 1h at 37°C. After one washing, 100µL/well of RBD r2 as antigen were added in concentrations from 0.12ng/mL to 30ng/mL diluted in 2% (w/v) nonfat dried milk powder in PBS. The plate was incubated 1 h at 37°C and next a wash step was performed. The MAb CBSSRBD-S.1 and MAb CBSSRBD-S.7

were previously conjugated to horseradish peroxidase by the method proposed by (Wilson and Nakane, 1978) . The CBSSRBD-S.1-HRP and CBSSRBD-S.7-HRP were diluted 1: 1600 or 1: 8000, respectively in PBS with 1% (w/v) nonfat dried milk powder. This step was performed using 100 µL/well of each respective (HRP)-labeled MAb and incubated for 1 h at 37°C. Finally, plates were washed and incubated in the dark with 100µL/well orto-phenylenediamine (0.5mg/mL, dissolved in 0.0243M citric acid, 0.0514M disodium hydrogen phosphate and 0.015% (w/v) hydrogen peroxide) for 20 min at RT. The reaction was stopped with 100µL/well 2M sulfuric acid and the A492nm was measured by the ELISA plate reader. Nonfat dried milk powder in PBS solution at 2% (w/v) was used as assay blank.

The assay was repeated during six non-consecutive days by two analysts (three assays per analyst). The interassay precision and accuracy of the back-calculated values for each standard concentration were used to determine the limits of quantification. The evaluation of precision was performed using the percentage of coefficient of variation (CV), calculated as CV = (SD/mean concentration) × 100. The evaluation of accuracy was performed using the relative error, calculated as error (%) = (calculated mean concentration -nominal concentration) × 100/nominal concentration. The lower limit of quantification was defined as the minimum value of the J o u r n a l P r e -p r o o f standard curve whose precision and accuracy was ≤20%. Correspondingly, the maximum value of the standard curve whose precision and accuracy was ≤15% was defined as the upper limit of quantification. This ELISA was also used for the quantification of the four other recombinant RBD-S antigens ( 

The neutralization antibody capability of the MAbs CBSSRBD-S.8 and CBSSRBD-S.11 were evaluated by a traditional virus microneutralization assay according to (Limonta-Fernández et al., 2021) using the SARS-CoV-2 strains D614G, and the variants of concern Alpha (lineage 

The highest antibody titers reached in serum from immunized mice was in order of 1:8900 at day 37 after the first immunization. These results were comparable with those obtained by Zakhartchouk et al. (2007) in a different SARS-CoV spike protein immunizations schedule, furthermore other authors reported a sub-optimal immunogenicity of RBD from SARS-CoV-2 (Mandolesi et al., 2020; Tan et al., 2021) . Therefore, the best tittered mouse was splenectomized and its splenocytes properly processed for the fusion with the myeloma cells.

Hybridomas obtained after fusion, were seeded in seventeen 96 wells plates. A total of 1632 wells were seeded. Ten days after the fusion 1510 wells were observed with hybrid cells growth that survived to the HAT supplemented selection medium, which represents a 92.5 % of fusion efficiency.

The ELISA screening of the cell culture supernatant allowed detecting twenty two wells as putative positive for secretion of specific MAbs against RBD-S, but only eight stable hybridomas cells line were obtained. Each one of them was three times cloned by limiting dilution method to ensure that cells that produce the antibody of interest were single-cell cloned and, consequently, the secretion of this antibody can be stably maintained. The hybridomas clones and its respective secreted MAbs were named (table 2) and isotyped as IgG 1 . These results confirmed that the immunization schedule, as well as the concentration of the antigen used was suitable for obtaining high fusion efficiency and to develop a successful generation of hybridomas.

The selected hybridoma cell lines were inoculated in BALB/c mice for ascites production. Ascites tumors were obtained in 100% of inoculated animals. MAbs purification from ascites was carried out by Protein A Sepharose affinity chromatography. Final yields obtained were between 1.0 and 2.5mg of purified MAbs per mL of ascitic fluid. The purity of MAbs was greater than 99%.

Four of the eight antibodies evaluated have affinity constant in the order of 10 8 L/mol. The MAbs CBSSRBD-S.7 and CBSSRBD-S.8 antibodies showed the highest affinity with very similar values (table 2) . Values for each antibody represent the mean ± SD of the six calculated K aff

The specificity of the MAbs generated against the RBD r1 antigen was evaluated by an inhibition assay with the RBD r1 and RBD r2 antigens. Even when the MAbs were generated against the RBD r1 protein, their specificity against this antigen was evaluated as a control for the functionality of the assay.

As expected, MAbs were highly inhibited by the antigen against which they were generated (RBD r1 ), except CBSSRBD-S.2 and CBSSRBD-S.3, which only inhibited 78.79% and 76.79%, respectively. This result was consistent with the fact that they were the lowest affinity antibodies (table 2) . Furthermore, both were the only MAbs that recognized RBD r1 under denaturing Western blot conditions (data not shown). This could suggest that these antibodies target a linear epitope partially occluded in a fully folded RBD molecule. The inhibition percentages with RBD r2 were equally high evidencing specific antigen-antibody recognition in solution, except with the MAbs CBSSRBD-S.2 and the CBSSRBD-S.3 (table 3) . In this case, the recognition site for these MAbs could be absent in RBD r2 , the shortest molecule of the antigens tested. This idea could be supported by the fact of no signal detection in Western blot (data not shown). These highly specific antibodies could be useful for the development of assays that require the recognition of both recombinant and natural antigens. 

The epitope competition between two antibodies was analyzed by an additivity ELISA. This assay requires the antigen to be saturated for each antibody tested. In order to ensure accuracy in determining the AI, it was established that coating the plate with 0.7µg/mL of RBD r1 and adding the MAbs in saturating concentrations (10µg/mL) guaranteed A492nm values between 0.400 and 0.500 for each antibody alone on the ELISA plate. The AI values of each pair of MAbs are shown in table 4. The AI data arranged on the diagonal and indicated in bold correspond to the AI zero . An arbitrary cut point is generally used in this kind of analysis e.g. (Haggarty et al., 1986; Liu et al., 2010; Zai et al., 2018) but this could affect the classification of antibodies in terms of the recognition of antigenic sites. Therefore, this work establishes a procedure to determine the cut point taking into account the distribution of random errors of the assay signal (A492nm). The use of the AI zero (additivity index of the same antibody) is the closest consideration to the AI obtained between two antibodies that compete for the same epitope. The cut point for AI in this trial was 41%, calculated from the formula described above and using t 0.05, 6 df = 1.943, SD = 16.06% and the mean of the IA zero = 9.79%.

The Data represent the AI calculated from triplicate absorbance values at 492 nm. The coefficient of variation of the absorbance values was less than 20%. The AI data arranged on the diagonal and indicated in bold, correspond to the AI zero . The mean of the AI zero was 9.79% and the SD was 16.06%. The cut point calculated, at 95% confidence, was AI≥41% (see formula defined above, for a t 0.05, 6df value of 1.943). If the two antibodies bind randomly at the same site the AI will be ˂41%. If the two antibodies bind independently at distinct sites AI will be ≥41%.

Since the MAbs CBSSRBD-S.8 and CBSSRBD-S.7 are the antibodies with the highest affinity (table 2) and recognize different epitopes (table 4) , they were selected to develop a sandwich ELISA that aimed to be used for quantification of RBD-S recombinant antigens in their production processes, as well as in the pharmacokinetic studies of RBD based vaccine candidates against SARS-CoV-2. As other authors have recommended (DeSilva et al., 2003) for standard curve fitting in immunoassays, five-parameter logistic regression was the best fit obtained for this RBD r2 standard curve ( figure 1A ). All points on the antigen curve were back-calculated with interassay precision and accuracy less than 9.91% and 4.85%, respectively. Standard curves are considered suitable at accuracy and precision ≤15% for each point, except at the lower limit of quantification, which could be ≤20% (DeSilva et al., 2003) . The range of quantification of standard curve was 0.121ng/mL to 7.50ng/mL. Due to the nature or format of many immunoassays, the quantification range of the standard curve can be very narrow, sometimes less than an order of magnitude (DeSilva et al., 2003) . The lower limit of quantification obtained with this combination of MAbs was 0.121ng/mL. If it were possible to quantify this antigen at the minimum required dilution recommended for immunoassays, between 1/20 and 1/100 (Mire-Sluis In order to broaden the quantification range of RBD r2 the MAb CBSSRBD-S.1 was conjugated to horseradish peroxidase. The MAb CBSSRBD-S.1 recognizes a different epitope than the CBSSRBD-S.8 (table 4) and has lower affinity than the CBSSRBD-S.7 (table 2) . With the new combination of MAbs (figure 1B), the five-parameter logistic regression was also the best fitted standard curve. All points on the antigen curve were back-calculated with interassay precision and accuracy of less than 9.05% and 15.92%, respectively. This new pair also allows a sensitive antigen determination, but with a wider quantification range for standard curve (0.272ng/mL to 29.8ng/mL). Taking into account the same minimum required dilution considerations with this 0.030 -19.5 ≤ 9.95 The range of quantification was based on the lower and upper limits of quantification, calculated from three independent trials. The error (%) represents the maximum error obtained between all points of the curve, as a measure of the accuracy of the back-calculated concentration by a five parameters logistic regression

A SARS-CoV-2 surrogate virus neutralization test (sVNT) that detects neutralizing antibodies targeting to RBD-S was performed. RBD r4 was selected to be conjugated to HRP considering that is human-Fc tagged and its large tag could avoid a possible interference of the enzyme conjugation in the RBD binding to the ACE-2 receptor. In addition, RBD r4 is a human recombinant protein with a folding and glycosylation profile similar to the viral protein.

Two of the above analyzed MAbs strongly inhibited the binding of RBDr4-HRP and hFc-ACE-2 in the sVNT (figure 2). The IC 50 calculated for the CBSSRBD-S.6 and CBSSRBD-S.8 MAbs was 2216.7pM and 122.7pM, respectively. These two MAbs have similar affinity constants (table 2) and recognize different epitopes (table 4) obtained with CBSSRBD-S.11was higher than those reported by Tan et al. (Tan et al., 2020) , who determined the inhibition of two MAbs in mice with IC 50 of 316.2pM and 197.2pM.

Consequently, CBSSRBD-S.11 showed the highest inhibition of the binding of RBD r4 -HRP and hFc-ACE-2. Engineering and Biotechnology, Havana, Cuba (unpublished results). This assay is being used to evaluate clinical trial patients with Cuban vaccines. Routine sVNT uses these neutralizing antibodies as a positive control. Moreover, these neutralizing MAbs could be valuables as biological reagents in researches about structural basis for RBD/ACE-2 binding mechanism, and even in preclinical therapeutic modeling. Data are the mean of triplicate measurements ± SD.

The potential therapeutic use of those MAbs that showed important neutralizing capacity has not scape to our attention. Even when MAbs have not been yet established as a relevant therapeutic tool for infected patients, the fact that high titer anti-RBD neutralizing antibody response has been considered as a correlate of immunity in vaccine development, suggests that the role of MAbs as therapeutics must be further explored. MAbs characteristics such as epitope specificity and neutralizing capacity, as well as the correct stratifications of patients in relation to time of infection or virus variants, could be important variables to assess in the road to find a place for therapeutics MAbs in COVID-19. It is well known that murine MAbs can generate undesirable immunogenic responses in humans that restrict their use as therapeutics. Humanized murine technology has been applied to derive neutralizing MAbs directed to the RBD-S protein Wu et al., 2020) . In that sense, the specificity and affinity for RBD-S of our neutralizing MAbs suggest that they could be humanized in order to test their therapeutic potential. Taking into account that these MAbs recognize different epitopes, the combination of them in therapy could be useful to reduce the events of antibody-resistant strains and avoid treatment failure, as explained Taylor et al. (Taylor et al., 2021) .

J o u r n a l P r e -p r o o f

Five of the murine antibodies obtained against the RBD protein of SARS-CoV-2 have affinities in the order of 10 8 L/mol. Six of them show a specific recognition of different recombinant RBDs in solution. A novel procedure for determining the additivity index cut point demonstrates that these anti-RBD antibodies recognize at least five different epitopes. Two MAbs reveal significant neutralization against SARS-CoV-2 in an ACE2-RBD binding inhibition assay and a neutralizing assay with intact SARS-CoV-2 virus. The high affinity MAbs, CBSSRBD-S.8 and CBSSRBD-S.7, recognize different epitopes and are therefore recommended for the development of a sandwich ELISA to quantify recombinant RBD-S antigens in biofabrication processes, in pharmacokinetic studies of preclinical and clinical trials, as well as other SARS-CoV-2 research projects.

This work was supported with funds from the BioCubaFarma, the Center for Genetic Engineering 

SARS-CoV-2 escape in vitro from a highly neutralizing COVID-19 convalescent plasma

SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface

Rapid development of neutralizing and diagnostic SARS-COV-2 mouse monoclonal antibodies

Emerging coronaviruses: Genome structure, replication, and pathogenesis

Tackling COVID-19 with neutralizing monoclonal antibodies

Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules

A convenient enzyme-linked immunosorbent assay for testing whether monoclonal antibodies recognize the same antigenic site. Application to hybridomas specific for the beta 2-subunit of Escherichia coli tryptophan synthase

Preparation of monoclonal antibodies: Strategies and procedures

Coronaviridae Study Group of the International Committee on Taxonomy of Viruses, 2020. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

Investigation of SARS-CoV-2 variants of concern: technical briefings

Potent mouse monoclonal antibodies that block SARS-CoV-2 infection

Epitopes of carcinoembryonic antigen defined by monoclonal antibodies prepared from mice immunized with purified carcinoembryonic antigen or HCT-8R cells

Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine

Development of a SARS-CoV-2-specific biosensor for antigen detection using scFv-Fc fusion proteins

Continuous cultures of fused cells secreting antibody of predefined specificity

A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury

SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. Npj Vaccines 6

A novel rapid detection for SARS-CoV-2 spike 1 antigens using human angiotensin converting enzyme 2 (ACE2)

Angiotensinconverting enzyme 2 is a functional receptor for the SARS coronavirus

The SARS-CoV-2 receptorbinding domain expressed in Pichia pastoris as a candidate vaccine antigen

Simple method of monoclonal antibody production against mammalian cellular prion protein

Neutralizing Monoclonal Anti-SARS-CoV-2 Antibodies Isolated from Immunized Rabbits Define Novel Vulnerable Spike-Protein Epitope

SARS-CoV-2 protein subunit vaccination elicits potent neutralizing antibody responses

Monoclonal Antibodies for Prevention and Treatment of COVID-19

Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products

Evaluation of a SARS-CoV-2 Surrogate Virus Neutralization Test for Detection of Antibody in Human, Canine, Cat, and Hamster Sera

Construction and immunogenic studies of a mFc fusion receptor binding domain (RBD) of spike protein as a subunit vaccine against SARS-CoV-2 infection

Rapid production of SARS-CoV-2 receptor binding domain (RBD) and spike specific monoclonal antibody CR3022 in Nicotiana benthamiana

A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction

Immunogenicity of prime-boost protein subunit vaccine strategies against SARS-CoV-2 in mice and macaques

Neutralizing monoclonal antibodies for treatment of COVID-19

Molecular Aspects Concerning the Use of the SARS-CoV-2 Receptor Binding Domain as a Target for Preventive Vaccines

SARS-CoV-2 RBD-Tetanus Toxoid Conjugate Vaccine Induces a Strong Neutralizing Immunity in Preclinical Studies

WHO Coronavirus (COVID-19) Dashboard | WHO Coronavirus (COVID-19) Dashboard With Vaccination Data

WHO, 2021c. COVID-19 vaccines

Draft landscape and tracker of COVID-19 candidate vaccines [WWW Document

speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefingon-covid

Recent development in the periodate method of conjugating horseradish peroxidase(HRPO) to antibodies., in: Immunofluorescence and Related Staining Techniques

Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies

Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2

Identification and characterization of a monoclonal antibody blocking the SARS-CoV-2 spike protein-ACE2 interaction

Dual monoclonal antibody-based sandwich ELISA for detection of in vitro packaged Ebola virus

Emergence of a novel SARS-CoV-2 strain in Southern California

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Receptor-binding domain as a target for developing SARS vaccines

The authors express thanks to the professors Emilio Carpio and Merardo Pujol, for their assistance in language and writing during the preparation of the manuscript. Also, we are grateful for the technical